Hemostatic composition and hemostatic method using hemostatic composition

Patent metadata

Field	Value
Publication number	US-2018360904-A1
Application number	US-201616060269-A
Country	US
Kind code	A1
Filing date	Dec 14, 2016
Priority date	Dec 18, 2015
Publication date	Dec 20, 2018
Grant date	—

Abstract

[Problem] To provide a composition for hemostasis that can be applied uniformly to a bleeding site and exerts a high hemostatic effect. [Solution] Provided is a composition to be applied to the subject as a spray, wherein the composition is characterized in that the spray is for hemostasis, and the composition includes a self-assembling peptide, the self-assembling peptide gelling due to self-assembly when the composition is applied to the bleeding site of the subject, and the self-assembling peptide being included in the composition in a concentration having an improved hemostatic capacity in comparison to direct application.

First claim

1 . A composition to be applied as a spray to a subject,
the spray being used for hemostasis, and the composition comprising a self-assembling peptide, wherein the self-assembling peptide self-assembles and thereby gels when the composition is applied to a bleeding site of the subject, and the self-assembling peptide is contained in the composition at a concentration at which the composition has an improved hemostatic ability as compared with that when directly applied.

2 . The composition according to claim 1 , wherein
the concentration of the self-assembling peptide in the composition is at least 1.5% by weight or higher.

3 . The composition according to claim 1 , wherein
the self-assembling peptide is (a) a peptide comprising an amino acid sequence consisting of 4 to 34 amino acid residues, wherein polar amino acid residues and nonpolar amino acid residues are alternately arranged, or (b) a peptide comprising an amino acid sequence consisting of 13 amino acid residues, wherein nonpolar amino acids and polar amino acids are arranged alternately and at symmetric positions in directions toward the N terminus and the C terminus centered on a nonpolar amino acid residue at position 7.

4 . The composition according to claim 3 , wherein
the polar amino acid residues are amino acid residues selected from the group consisting of an aspartic acid residue, a glutamic acid residue, an arginine residue, a lysine residue, a histidine residue, a tyrosine residue, a serine residue, a threonine residue, an asparagine residue, a glutamine residue, and a cysteine residue.

5 . The composition according to claim 3 , wherein
the nonpolar amino acid residues are amino acid residues selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a methionine residue, a phenylalanine residue, a tryptophan residue, a proline residue, and a glycine residue.

6 . The composition according to claim 3 , wherein
the polar amino acid residues are amino acid residues selected from the group consisting of an aspartic acid residue, a glutamic acid residue, an arginine residue, a lysine residue, a histidine residue, a tyrosine residue, a serine residue, a threonine residue, an asparagine residue, a glutamine residue, and a cysteine residue, and the nonpolar amino acid residues are amino acid residues selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a methionine residue, a phenylalanine residue, a tryptophan residue, a proline residue, and a glycine residue.

7 . The composition according to claim 6 , wherein
the self-assembling peptide is a peptide comprising RADARADARADARADA (SEQ ID NO: 1), a peptide comprising IEIKIEIKIEIKI (SEQ ID NO: 2), or a peptide comprising RLDLRLALRLDLR (SEQ ID NO: 3).

8 . The composition according to claim 7 , wherein
the self-assembling peptide is a peptide consisting of RADARADARADARADA (SEQ ID NO: 1), a peptide consisting of IEIKIEIKIEIKI (SEQ ID NO: 2), or a peptide consisting of RLDLRLALRLDLR (SEQ ID NO: 3).

9 . The composition according to claim 1 , wherein
the bleeding site of the subject is a non-surgically formed wound site or a surgically formed incision site or excision site.

10 . (canceled)

11 . A spray comprising the composition of claim 1 .

12 . A method for hemostasis in a subject, comprising the step of
applying a composition comprising a self-assembling peptide to a bleeding site of the subject by spraying, wherein the self-assembling peptide self-assembles and thereby gels when the composition is applied to the bleeding site of the subject, and the self-assembling peptide is contained in the composition at a concentration at which the composition has an improved hemostatic ability as compared with that when directly applied.

13 . The method according to claim 12 , wherein
the concentration of the self-assembling peptide in the composition is at least 1.5% by weight or higher.

14 . The method according to claim 12 , wherein
the bleeding site of the subject is a non-surgically formed wound site or a surgically formed incision site or excision site.

15 . The method according to claim 12 , wherein
the subject is a nonhuman animal.

Assignees

• 3 D Matrix Ltd

Inventors

• Nagano Keiji
• Kobayashi Satoru

Classifications

• A61L26/0028

  Polypeptides; Proteins; Degradation products thereof · CPC title

• A61K9/7015

  Drug-containing film-forming compositions, e.g. spray-on · CPC title

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K9/12 Primary

  Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)} · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title